Response to "Unexpected mutations after CRISPR-Cas9 editing in vivo"
- PMID: 29600992
- PMCID: PMC7784551
- DOI: 10.1038/nmeth.4541
Response to "Unexpected mutations after CRISPR-Cas9 editing in vivo"
Conflict of interest statement
Conflict of interest statement
J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Monitor Biotechnologies, Pairwise Plants, Poseida Therapeutics, and Transposagen Biopharmaceuticals. M.J.A. has financial interests in Monitor Biotechnologies. J.K.J.’s and M.J.A.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.
Figures
Comment on
-
Unexpected mutations after CRISPR-Cas9 editing in vivo.Nat Methods. 2017 May 30;14(6):547-548. doi: 10.1038/nmeth.4293. Nat Methods. 2017. PMID: 28557981 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
